SecBot SecBot
PRESS-RELEASE ·Filed Aug 28, 2026

AMRN

Amarin Corporation plc
NEUTRAL
Impact 4/10
Horizondays Processed2mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This is a scientific update with no immediate financial or regulatory impact. Traders should watch for any subsequent regulatory or commercial developments, but this press release alone is unlikely to be a catalyst.

DirectionNeutral
Confidencemedium
Horizondays

IPE

▼ Bearish Named in this press release
Impact
Phase
Approved
Time to market
Already on the market (approved 2012, expanded label 2019)
Next catalyst
None dated

What to watchWatch the Q3 2026 earnings release (~Oct 27–Nov 4) for updates on US market share erosion, net pricing trends, and international volume growth via Recordati. Key to watch: whether branded US market share can stabilize above 45% and whether operating expense cuts continue to offset top-line pressure. The EMT2 oncology results, while scientifically interesting, are not a near-term commercial catalyst and do not change the fundamental generic-overhang thesis.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$13.97
T+0 close · Aug 28, 2026 · via day close
Latest settled
−5.15%
T+20 · $13.25 · next T+60 in 6d
Vs SPY
−5.41%
α at T+20
Latest observation
−15.02%
T+54 · FF3 residual α
  1. T+0 · Aug 28 $13.97entry
  2. T+1 · 3mo ago −0.64%α −0.35% · $13.88
  3. T+5 · 2mo ago −2.43%α −2.54% · $13.63
  4. T+20 · 7w ago −5.15%α −5.41% · $13.25
  5. T+55 · todayOpen
  6. T+60 · in 6d Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Amarin announced a post-hoc analysis from the REDUCE-IT trial at ESC 2026, showing that highly adherent patients on icosapent ethyl (IPE) experienced ~30% relative risk reduction in MACE, and that benefits may persist for years after discontinuation (legacy effect). This is a scientific update on an already-approved drug, not a regulatory catalyst or new revenue driver, and does not change the company's commercial outlook or financial position.

Key Facts

  • Post-hoc analysis of REDUCE-IT showed ~30% RRR in primary endpoint for high adherers on IPE for ≥1.5 years.
  • Secondary prevention patients who stopped IPE after mean 2.3 years maintained HR of 0.73 for events occurring after discontinuation (legacy effect).
  • The analysis is exploratory and presented at ESC 2026; no new regulatory or commercial catalyst.
  • Amarin's market cap is ~$297M with 0% analyst bullishness and recent insider selling.

Financial Impact

No financial figures reported; the analysis does not change revenue, earnings, or guidance.

Risk Factors

  • No new revenue or regulatory catalyst; the analysis is exploratory and does not change the commercial outlook.
  • Historical underperformance on similar updates suggests limited positive price reaction.
  • Low analyst bullishness (0%) and recent insider selling indicate weak sentiment.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3352671

Track record

8 reports on AMRN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Oct 28, 202619d ago 8-K Neutral 5/10 No price data
  2. Oct 28, 202619d ago Press Release Neutral 5/10 Entry $12.75 Now $11.31 −11.26% settles Jan 26
  3. Oct 25, 202622d ago Press Release Mixed 6/10 Entry $12.09 Now $11.31 −6.45% settles Jan 22
  4. Aug 28, 202611w ago Press Release Neutral 4/10 Viewing Entry $13.97 Now $11.31 −19.04% settles Nov 23
  5. Jun 4, 202623w ago Court Ruling Bearish 7/10 Entry $13.80 to $13.97 Now $11.31 +18.04% ▼ −1.23% +0.65% vs SPY
  6. Apr 29, 202628w ago 8-K Neutral 4/10 Entry $14.29 to $13.55 Now $11.31 −20.85% ▼ −5.18% −9.29% vs SPY
  7. Mar 16, 202635w ago Press Release Neutral 4/10 Entry $15.42 to $14.20 Now $11.31 −26.65% ▼ −7.91% −18.40% vs SPY
  8. Feb 25, 202637w ago 8-K Bearish 6/10 Entry $14.05 to $14.27 Now $11.31 +19.50% ▼ −1.57% +5.38% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens Wed (11h 29m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 28, 2026